Corporate Profile

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about Jaguar Health, please visit For more information about Napo Pharmaceuticals, visit For more information about Napo Therapeutics, visit For more information about Magdalena Biosciences, visit

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Featured Events

Sep 7, 2023
Jaguar Presentation at September 7, 2023 Emerging Growth Conference

Recent News

September 21, 2023
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
September 14, 2023
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
September 13, 2023
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)